ARX

ARX is in Stage 2 corrective advance within its longer-term downtrend, and the Bullish Pivot Point signals that downside control has failed and structural repair is underway. The mid-July bounce held above rising 9/21 EMAs, invalidating the prior bearish posture and establishing a bullish medium-term bias. Short-term execution is favorable now as price tightly tracks above EMAs without exhaustion. Buy on support near the 9/21 EMA zone, while resistance at the 50-DMA and potential Stage 3 transition remain key considerations.

• ↑Revenue rose 54% YoY to $273M in Q1
• ↑Adjusted EBITDA jumped 69% YoY to $66M
• ↓Operational cash flow was -$21M in Q1, straining liquidity